Santhera Pharmaceuticals Holding AG (SIX: SANN), a Swiss based company announced that they will present data from an on-going Expanded Access Program (EAP) for their LHON treatment at the 2014 Annual Meeting of the North American Neuro-Ophthalmology Society (NANOS) in Puerto Rico. The company’s “Raxone” drug for Leber’s hereditary optic neuropathy has previously demonstrated that 50% of patients have achieved a clinically relevant improvement in their vision and 63% of the patients were protected from further vision loss following treatment. The drug was reported as safe and well tolerated following long-term use in the EAP.